Polymorphisms in immune checkpoint genes might influence bladder cancer risk and clinical outcome
BACKGROUND: In addition to well-established immune checkpoints (ICs), such as CTLA-4, PD-1, PD-L1, increasing attention is being directed toward next-generation ICs, including TIM-3, Gal-9, LAG-3, BTLA, HVEM, and CD160. Single nucleotide polymorphisms (SNPs) within IC-related genes may contribute to dysregulation of inhibitory pathways and impair anti-tumor immune responses. This study aimed to evaluate the association between selected IC gene variants and susceptibility to bladder cancer (BC). PATIENTS AND METHODS: A total of twelve SNPs located in TIM-3, LGALS9, BTLA, HVEM, and CD160 genes were genotyped using TaqMan assays in 314 BC patients and over 520 healthy controls (HC). Genotype distributions were analyzed under multiple genetic models, and associations with clinicopathological parameters were assessed using multivariate logistic regression. RESULTS: Genotype distributions of BTLA polymorphisms (rs2705511, rs1982809, rs9288953) differed between BC patients and HC, suggesting potential associations with BC risk. Stratified analyses revealed sex-specific effects, with variants in BTLA (rs1982809), HVEM (rs1886730, rs2234167, rs8725), and CD160 (rs231375) showing potential associations with susceptibility among women. Additionally, SNPs in BTLA and HVEM were nominally associated with recurrence and high-grade tumors, while CD160 and LGALS9 variants were potentially linked to primary tumor occurrence. However, these associations lost statistical significance after correction for multiple comparisons. CONCLUSIONS: Although the observed associations did not remain significant after multiple testing correction, the results suggest that genetic variation within BTLA, HVEM, and CD160 genes may still play a biologically relevant role in BC susceptibility and disease progression. These findings underscore the potential importance of IC pathways in BC pathogenesis and warrant further investigation in larger, well-powered studies.
Authors
- Emilia Jaskuła (ORCID: https://orcid.org/0000-0002-4894-7522)
- Anna Tomkiewicz (ORCID: https://orcid.org/0000-0002-9722-9359)
- Anna Andrzejczak (ORCID: https://orcid.org/0000-0001-6098-7554)
- Bartosz Małkiewicz (ORCID: https://orcid.org/0000-0002-5933-3753)
- Tomasz Szydełko (ORCID: https://orcid.org/0000-0002-1360-0422)
- Lidia Karabon (ORCID: https://orcid.org/0000-0001-8172-0971)
- Wojciech Krajewski
- Joanna Chorbińska
Institutions
- Center for Special Minimally Invasive and Robotic Surgery (US)
- Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (PL)
Publication Details
- Journal
- Human Immunology
- Published
- 2026-06-12
- DOI
- https://doi.org/10.1016/j.humimm.2026.111783
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu
- Instytut Immunologii i Terapii Doświadczalnej, im. Ludwika Hirszfelda Polskiej Akademii Nauk